Seeking participants for a study of a new treatment for Alzheimer’s disease
Research has shown a relationship between higher levels of brain iron, the presence of the Alzheimer’s protein, amyloid, and poorer memory and language skills. The purpose of this study is to test the effects of Deferiprone on your disease.
Deferiprone (fast release formulation) is approved in Australia to treat Thalassemia, a blood disorder in which the body makes an abnormal form of red blood cells. However, Deferiprone in a different form (now a delayed release formulation) is an experimental treatment for early AD. This means it is not approved and must be tested to see if it is an effective treatment. It is not guaranteed to treat early AD.
Anticipated date that enrolment will close: December 2021
Who can take part
- Aged >55 years with a diagnosis of early Alzheimer's disease (MMSE)
- Living in the community
- On stable medications
What is involved for you
- 3-monthly visits to the Royal Melbourne Hospital for the duration of the study
- Cognitive testing (memory, processing of information) every 3 months
- 2 x MRI (magnetic resonance imaging)
- Weekly bloods to be taken at local Dorevitch Pathology for first 6 months
No payments are made for participating in studies at The Royal Melbourne Hospital other than reimbursement for travel and expenses, which may be applicable.